Cellectis (CLLS) Income from Continuing Operations (2015 - 2026)
Cellectis' (CLLS) quarterly Income from Continuing Operations came in at 8830000.0 in Q1 2026, down 473.36% year-on-year from 2365000.0 in Q1 2025, and up 91.67% quarter-over-quarter from 106058000.0 in Q4 2025.
Cellectis (CLLS) Income from Continuing Operations (2015 - 2026) Analysis & Trends
Cellectis' Income from Continuing Operations history runs 12 years deep, the most recent figure standing at 8830000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 473.36% year-over-year to 8830000.0 in Q1 2026; TTM through Mar 2026 was 76822000.0, a 223.23% decrease from a year earlier, with the FY2025 full-year figure at 67593000.0, down 83.87% from the prior year.
- Income from Continuing Operations grew to 8830000.0 in Q1 2026 per CLLS's latest filing, from 106058000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 22412000.0 in Q3 2025 and bottomed at 106058000.0 in Q4 2025.
- The 5-year median for Income from Continuing Operations is 8830000.0 (2026), against an average of 18569529.41.
- Across the five-year window, Income from Continuing Operations plunged 3000.67% in 2023 and surged 191.03% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 2837000.0 in 2022, then plunged by 3000.67% to 87966000.0 in 2023, then soared by 52.64% to 41663000.0 in 2024, then plunged by 154.56% to 106058000.0 in 2025, then surged by 91.67% to 8830000.0 in 2026.
- Per Business Quant, the three latest CLLS Income from Continuing Operations figures stand at 8830000.0 (Q1 2026), 106058000.0 (Q4 2025), and 22412000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Cellectis | 285.50 Mn | 99.83 Mn | - | -8.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.83 Mn |
| Dec 31, 2025 | -106.06 Mn |
| Sep 30, 2025 | 22.41 Mn |
| Jun 30, 2025 | 15.65 Mn |
| Mar 31, 2025 | 2.37 Mn |
| Dec 31, 2024 | -41.66 Mn |
| Sep 30, 2024 | 7.70 Mn |
| Jun 30, 2024 | 7.83 Mn |
| Mar 31, 2024 | 11.65 Mn |
| Dec 31, 2023 | -87.97 Mn |
| Sep 30, 2023 | -38.94 Mn |
| Jun 30, 2023 | -34.90 Mn |
| Mar 31, 2023 | -17.48 Mn |
| Dec 31, 2022 | -2.84 Mn |
| Sep 30, 2022 | -23.37 Mn |
| Jun 30, 2022 | -15.63 Mn |
| Mar 31, 2022 | -5.62 Mn |
| Dec 31, 2021 | -7.06 Mn |
| Sep 30, 2021 | -44.56 Mn |
| Jun 30, 2021 | -36.17 Mn |